Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13086576 | 0.87 | ALDH1A1 (0.36) | MEN1NPC1ALDH1A1POLBMAPT | |
| SCHEMBL26669664 | 0.76 | NOS3 (0.33) | NPC1ALDH1A1RAB9A | |
| SCHEMBL798520 | 0.72 | ALDH1A1 (0.33) | NPC1ALDH1A1RAB9A | |
| SCHEMBL19756600 | 0.72 | POLB (0.32) | POLB | |
| SCHEMBL24712163 | 0.71 | SCN10A (0.33) | — | |
| SCHEMBL10811668 | 0.71 | CYP1A2 (0.33) | NPC1MAPTRAB9A | |
| SCHEMBL18806212 | 0.71 | MAPK14 (0.34) | MEN1NPC1ALDH1A1POLBMAPT | |
| SCHEMBL23197730 | 0.70 | ALDH1A1 (0.33) | MEN1NPC1ALDH1A1POLBMAPT | |
| SCHEMBL18819911 | 0.70 | ALDH1A1 (0.33) | MEN1NPC1ALDH1A1POLBMAPT | |
| SCHEMBL25098988 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | MEN1 400/4885NPC1 2134/4885ALDH1A1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.